Shattuck Labs, Inc. 8-K

What Happened

• Shattuck Labs, Inc. announced on June 9, 2026 that it entered into an underwriting agreement with Leerink Partners, J.P. Morgan Securities, Piper Sandler and Cantor Fitzgerald to sell common stock and pre-funded warrants. The offering consisted of 10,879,376 shares of common stock at $4.00 per share and 7,870,624 pre-funded warrants at $3.9999 each. The underwriters exercised a 30-day option in full on June 10, 2026 to purchase an additional 2,812,500 shares. The offering was expected to close on June 11, 2026.

Key Details

• Gross proceeds (before underwriting discounts/commissions): approximately $86.25 million (21,562,500 units at $4.00 each).
• Pre-funded warrants are exercisable immediately; each has a $0.0001 exercise price and limits on exercise to avoid exceeding beneficial ownership thresholds (default caps of 4.99% or 9.99%, with the holder able to elect up to 19.99% with 61 days’ notice).
• Offering conducted under the company’s shelf registration (File No. 333-292697); final prospectus supplement dated June 9, 2026 filed with the SEC June 11, 2026.
• The underwriting agreement includes customary representations, closing conditions and indemnities; legal opinion from Gibson, Dunn & Crutcher LLP was filed.

Why It Matters

• This financing raises fresh capital that can support Shattuck Labs’ operations, development programs and balance sheet without immediate dilution from warrant exercises (pre-funded warrants are used to limit immediate common share issuance).
• The size and terms (including ownership caps on pre-funded warrant exercises) affect shareholder dilution and potential future share supply — information investors should consider when evaluating ownership percentage and near-term capital needs.